Z. Ping Lin, PhD
Research Scientist
Research & Publications
Biography
News
Coauthors
Selected Publications
- Poly (ADP-ribose) polymerase inhibitorsRatner ES, Sartorelli AC, Lin ZP. Poly (ADP-ribose) polymerase inhibitors. Current Opinion In Oncology 2012, 24: 564-571. PMID: 22759740, PMCID: PMC3799945, DOI: 10.1097/cco.0b013e3283564230.
- In silico screening identifies a novel small molecule inhibitor that counteracts PARP inhibitor resistance in ovarian cancerLin ZP, Al Zouabi NN, Xu ML, Bowen NE, Wu TL, Lavi ES, Huang PH, Zhu YL, Kim B, Ratner ES. In silico screening identifies a novel small molecule inhibitor that counteracts PARP inhibitor resistance in ovarian cancer. Scientific Reports 2021, 11: 8042. PMID: 33850183, PMCID: PMC8044145, DOI: 10.1038/s41598-021-87325-5.
- Triapine Disrupts CtIP-Mediated Homologous Recombination Repair and Sensitizes Ovarian Cancer Cells to PARP and Topoisomerase InhibitorsLin ZP, Ratner ES, Whicker ME, Lee Y, Sartorelli AC. Triapine Disrupts CtIP-Mediated Homologous Recombination Repair and Sensitizes Ovarian Cancer Cells to PARP and Topoisomerase Inhibitors. Molecular Cancer Research 2014, 12: 381-393. PMID: 24413181, PMCID: PMC3962722, DOI: 10.1158/1541-7786.mcr-13-0480.
- Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancerLin ZP, Zhu YL, Lo YC, Moscarelli J, Xiong A, Korayem Y, Huang PH, Giri S, LoRusso P, Ratner ES. Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer. PLOS ONE 2018, 13: e0207399. PMID: 30444904, PMCID: PMC6239325, DOI: 10.1371/journal.pone.0207399.
- Targeting Cyclin-Dependent Kinases for Treatment of Gynecologic CancersLin ZP, Zhu YL, Ratner ES. Targeting Cyclin-Dependent Kinases for Treatment of Gynecologic Cancers. Frontiers In Oncology 2018, 8: 303. PMID: 30135856, PMCID: PMC6092490, DOI: 10.3389/fonc.2018.00303.
- Gene expression of non-homologous end-joining pathways in the prognosis of ovarian cancerLavi E, Lin Z, Ratner E. Gene expression of non-homologous end-joining pathways in the prognosis of ovarian cancer. IScience 2023, 26: 107934. PMID: 37810216, PMCID: PMC10558711, DOI: 10.1016/j.isci.2023.107934.
- Transforming Growth Factor Beta and Epithelial to Mesenchymal Transition Alter Homologous Recombination Repair Gene Expression and Sensitize BRCA Wild-Type Ovarian Cancer Cells to OlaparibRoberts C, Rojas-Alexandre M, Hanna R, Lin Z, Ratner E. Transforming Growth Factor Beta and Epithelial to Mesenchymal Transition Alter Homologous Recombination Repair Gene Expression and Sensitize BRCA Wild-Type Ovarian Cancer Cells to Olaparib. Cancers 2023, 15: 3919. PMID: 37568736, PMCID: PMC10417836, DOI: 10.3390/cancers15153919.
- Flow Cytometric Analyses of p53-Mediated Cell Cycle Arrest and Apoptosis in Cancer CellsAl Zouabi NN, Roberts CM, Lin ZP, Ratner ES. Flow Cytometric Analyses of p53-Mediated Cell Cycle Arrest and Apoptosis in Cancer Cells. 2020, 2255: 43-53. PMID: 34033093, DOI: 10.1007/978-1-0716-1162-3_5.
- Transforming growth factor downregulates homologous recombination repair genes and increases PARP inhibitor sensitivity in BRCA2 wild-type epithelial ovarian cancer cellsAlexandre M, Lin Z, Hanna R, Ratner E. Transforming growth factor downregulates homologous recombination repair genes and increases PARP inhibitor sensitivity in BRCA2 wild-type epithelial ovarian cancer cells. Gynecologic Oncology 2018, 149: 69. DOI: 10.1016/j.ygyno.2018.04.156.
- Triapine-olaparib combination therapy deters peritoneal progression of PARP inhibitor-resistant epithelial ovarian cancerLin Z, Zhu Y, Huang P, Ratner E. Triapine-olaparib combination therapy deters peritoneal progression of PARP inhibitor-resistant epithelial ovarian cancer. Gynecologic Oncology 2018, 149: 74. DOI: 10.1016/j.ygyno.2018.04.168.
- Combination of triapine, olaparib, and cediranib for epithelial ovarian cancer therapy.Lin Z, Zhu Y, Schwartz P, Ratner E. Combination of triapine, olaparib, and cediranib for epithelial ovarian cancer therapy. Journal Of Clinical Oncology 2018, 36: e17551-e17551. DOI: 10.1200/jco.2018.36.15_suppl.e17551.
- Abstract 850: The Pi3K/Akt pathway mediates epithelial-mesenchymal transition (EMT) and malignant progression in BRCA-defective epithelial ovarian cancerAlexandre M, Lin Z, Ratner E. Abstract 850: The Pi3K/Akt pathway mediates epithelial-mesenchymal transition (EMT) and malignant progression in BRCA-defective epithelial ovarian cancer. Cancer Research 2017, 77: 850-850. DOI: 10.1158/1538-7445.am2017-850.
- MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparibWhicker ME, Lin ZP, Hanna R, Sartorelli AC, Ratner ES. MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib. BMC Cancer 2016, 16: 550. PMID: 27465688, PMCID: PMC4964088, DOI: 10.1186/s12885-016-2598-1.
- Triapine potentiates platinum-based combination therapy by disruption of homologous recombination repairRatner ES, Zhu YL, Penketh PG, Berenblum J, Whicker ME, Huang PH, Lee Y, Ishiguro K, Zhu R, Sartorelli AC, Lin ZP. Triapine potentiates platinum-based combination therapy by disruption of homologous recombination repair. British Journal Of Cancer 2016, 114: 777-786. PMID: 26964031, PMCID: PMC4984868, DOI: 10.1038/bjc.2016.54.
- Antitumor activity of the ribonucleotide reductase inhibitor Triapine alone or in combination with paclitaxelIshiguro K, Lin Z, Rutherford T, Ratner E. Antitumor activity of the ribonucleotide reductase inhibitor Triapine alone or in combination with paclitaxel. Gynecologic Oncology 2015, 137: 79. DOI: 10.1016/j.ygyno.2015.01.193.
- p53 protein aggregation promotes platinum resistance in ovarian cancerYang-Hartwich Y, Soteras MG, Lin ZP, Holmberg J, Sumi N, Craveiro V, Liang M, Romanoff E, Bingham J, Garofalo F, Alvero A, Mor G. p53 protein aggregation promotes platinum resistance in ovarian cancer. Oncogene 2014, 34: 3605-3616. PMID: 25263447, DOI: 10.1038/onc.2014.296.
- MK-2206 sensitizes BRCA2 mutant ovarian adenocarcinoma to cisplatin and poly ADP (adenosine diphosphate)-ribose polymerase (PARP) inhibitor therapyWhicker M, Lin Z, Sartorelli A, Ratner E. MK-2206 sensitizes BRCA2 mutant ovarian adenocarcinoma to cisplatin and poly ADP (adenosine diphosphate)-ribose polymerase (PARP) inhibitor therapy. Gynecologic Oncology 2014, 133: 86-87. DOI: 10.1016/j.ygyno.2014.03.231.
- Abstract 3277: Pifithrin-α and veliparib synergize in the sensitization of p53 wild-type ovarian cells to cisplatin therapy.Whicker M, Liang B, Lin Z, Sartorelli A, Ratner E. Abstract 3277: Pifithrin-α and veliparib synergize in the sensitization of p53 wild-type ovarian cells to cisplatin therapy. Cancer Research 2013, 73: 3277-3277. DOI: 10.1158/1538-7445.am2013-3277.
- Abstract 4490: Triapine sensitizes chemoresistant ovarian cancer cells to platinum therapy.Ratner E, Whicker M, Lin Z, Sartorelli A. Abstract 4490: Triapine sensitizes chemoresistant ovarian cancer cells to platinum therapy. Cancer Research 2013, 73: 4490-4490. DOI: 10.1158/1538-7445.am2013-4490.
- Targeting the upregulation of the AKT pathway and homologous recombination repair as a therapeutic strategy for epithelial ovarian cancer.Ratner E, Lin Z, Rutherford T, Azodi M, Santin A, Schwartz P, Sartorelli A. Targeting the upregulation of the AKT pathway and homologous recombination repair as a therapeutic strategy for epithelial ovarian cancer. Journal Of Clinical Oncology 2012, 30: e13125-e13125. DOI: 10.1200/jco.2012.30.15_suppl.e13125.
- Abstract 2743: Triapine sensitizes ovarian cancer cells to platinum drugs and PARP inhibitorsLin Z, Ratner E, Sartorelli A. Abstract 2743: Triapine sensitizes ovarian cancer cells to platinum drugs and PARP inhibitors. Cancer Research 2012, 72: 2743-2743. DOI: 10.1158/1538-7445.am2012-2743.
- Reduced Level of Ribonucleotide Reductase R2 Subunits Increases Dependence on Homologous Recombination Repair of Cisplatin-Induced DNA DamageLin ZP, Lee Y, Lin F, Belcourt MF, Li P, Cory JG, Glazer PM, Sartorelli AC. Reduced Level of Ribonucleotide Reductase R2 Subunits Increases Dependence on Homologous Recombination Repair of Cisplatin-Induced DNA Damage. Molecular Pharmacology 2011, 80: 1000-1012. PMID: 21875941, PMCID: PMC3228527, DOI: 10.1124/mol.111.074708.
- Disruption of cAMP and Prostaglandin E2 Transport by Multidrug Resistance Protein 4 Deficiency Alters cAMP-Mediated Signaling and Nociceptive ResponseLin ZP, Zhu YL, Johnson DR, Rice KP, Nottoli T, Hains BC, McGrath J, Waxman SG, Sartorelli AC. Disruption of cAMP and Prostaglandin E2 Transport by Multidrug Resistance Protein 4 Deficiency Alters cAMP-Mediated Signaling and Nociceptive Response. Molecular Pharmacology 2007, 73: 243-251. PMID: 17959714, PMCID: PMC2780335, DOI: 10.1124/mol.107.039594.
- Ataxia-telangiectasia mutated kinase regulates ribonucleotide reductase and mitochondrial homeostasisEaton JS, Lin ZP, Sartorelli AC, Bonawitz ND, Shadel GS. Ataxia-telangiectasia mutated kinase regulates ribonucleotide reductase and mitochondrial homeostasis. Journal Of Clinical Investigation 2007, 117: 2723-2734. PMID: 17786248, PMCID: PMC1952633, DOI: 10.1172/jci31604.
- Excess ribonucleotide reductase R2 subunits coordinate the S phase checkpoint to facilitate DNA damage repair and recovery from replication stressLin ZP, Belcourt MF, Carbone R, Eaton JS, Penketh PG, Shadel GS, Cory JG, Sartorelli AC. Excess ribonucleotide reductase R2 subunits coordinate the S phase checkpoint to facilitate DNA damage repair and recovery from replication stress. Biochemical Pharmacology 2006, 73: 760-772. PMID: 17188250, DOI: 10.1016/j.bcp.2006.11.014.
- Resistance to purine and pyrimidine nucleoside and nucleobase analogs by the human MDR1 transfected murine leukemia cell line L1210/VMDRC.06Zeng H, Lin ZP, Sartorelli AC. Resistance to purine and pyrimidine nucleoside and nucleobase analogs by the human MDR1 transfected murine leukemia cell line L1210/VMDRC.06. Biochemical Pharmacology 2004, 68: 911-921. PMID: 15294454, DOI: 10.1016/j.bcp.2004.06.004.
- Stable Suppression of the R2 Subunit of Ribonucleotide Reductase by R2-targeted Short Interference RNA Sensitizes p53(–/–) HCT-116 Colon Cancer Cells to DNA-damaging Agents and Ribonucleotide Reductase Inhibitors*Lin ZP, Belcourt MF, Cory JG, Sartorelli AC. Stable Suppression of the R2 Subunit of Ribonucleotide Reductase by R2-targeted Short Interference RNA Sensitizes p53(–/–) HCT-116 Colon Cancer Cells to DNA-damaging Agents and Ribonucleotide Reductase Inhibitors*. Journal Of Biological Chemistry 2004, 279: 27030-27038. PMID: 15096505, DOI: 10.1074/jbc.m402056200.
- Age-Related Differences in Vincristine Toxicity and Biodistribution in Wild-Type and Transporter-Deficient MiceMuramatsu T, Johnson DR, Finch RA, Johnson LK, Leffert JJ, Lin ZP, Pizzorno G, Sartorelli AC. Age-Related Differences in Vincristine Toxicity and Biodistribution in Wild-Type and Transporter-Deficient Mice. Oncology Research Featuring Preclinical And Clinical Cancer Therapeutics 2004, 14: 331-343. PMID: 15301424, DOI: 10.3727/0965040041292387.
- Comparative study of the importance of multidrug resistance-associated protein 1 and P-glycoprotein to drug sensitivity in immortalized mouse embryonic fibroblasts.Lin ZP, Johnson DR, Finch RA, Belinsky MG, Kruh GD, Sartorelli AC. Comparative study of the importance of multidrug resistance-associated protein 1 and P-glycoprotein to drug sensitivity in immortalized mouse embryonic fibroblasts. Molecular Cancer Therapeutics 2002, 1: 1105-14. PMID: 12481434.